Alpha Paradigm Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Alpha Paradigm Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$2.01M	Buy	6,963 +3,409	+96%	+$1.04M	0.83%	14
2022 Q3	$1.03M	Buy	+3,554	New	+$1.02M	0.45%	62
2022 Q2	–	Sell	-2,259	Closed	-$590K	–	649
2022 Q1	$590K	Buy	2,259 +1,061	+89%	+$252K	0.23%	137
2021 Q4	$263K	Buy	1,198 +140	+13%	+$27.2K	0.11%	297
2021 Q3	$192K	Sell	1,058 -9,314	-90%	-$1.82M	0.08%	343
2021 Q2	$2.09M	Buy	+10,372	New	+$2.17M	0.79%	10
2021 Q1	–	Sell	-1,051	Closed	-$248K	–	641
2020 Q4	$248K	Buy	+1,051	New	+$241K	0.09%	245

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Alpha Paradigm Partners's VRTX Position: Q4 2022 in Review

Alpha Paradigm Partners increased its Vertex Pharmaceuticals (VRTX) stake by 96% in Q4 2022, buying an estimated $1.04M and bringing the position to 6,963 shares worth $2.01M. The position accounts for 0.83% of the portfolio, ranked #14.

Alpha Paradigm Partners first reported a position in VRTX in Q4 2020 and has held it in 7 quarters since. The position peaked at $2.09M in Q2 2021. 1,222 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

Alpha Paradigm Partners held 6,963 shares of Vertex Pharmaceuticals worth $2.01M as of Q4 2022.
Alpha Paradigm Partners bought 3,409 Vertex Pharmaceuticals shares in Q4 2022, an estimated $1.04M.
Vertex Pharmaceuticals made up 0.83% of Alpha Paradigm Partners's portfolio in Q4 2022, its #14 holding.
Alpha Paradigm Partners first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 7 quarters since.
Alpha Paradigm Partners's Vertex Pharmaceuticals position peaked at $2.09M in Q2 2021.
1,222 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on Alpha Paradigm Partners's 13F filing for Q4 2022, filed 13 Feb 2023.